Vectibix increases progression-free survival in trial

08/7/2009 | Reuters

Colorectal cancer patients with the normal version of the KRAS gene had increased progression-free survival when treated initially with Vectibix and chemotherapy, compared to chemotherapy alone, a clinical study showed. Reported side effects included diarrhea, skin toxicity and low magnesium blood levels.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC